Restructurings (Tables)
|
12 Months Ended |
Jun. 30, 2026 |
|---|
| Fiscal Year 2026 Restructuring Actions |
|
| Restructuring |
|
| Schedule of restructuring charges |
The restructuring and restructuring-related changes for periods presented were recorded in the Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands): | | | | | | Year Ended | | | June 30, | | | 2026 | Cost of sales | | $ | — | Selling, general and administrative | | | 4,231 | Total | | $ | 4,231 |
| (1) | Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. |
Restructuring and restructuring-related costs by segment are as follows (in thousands): | | | | | | | | | | | | Year ended June 30, 2026 | | | | Employee | | | Asset-related | | | | | | | severance | | | and other | | | Total | Protein Sciences | | $ | 278 | | $ | 713 | | $ | 991 | Diagnostics and Spatial Biology | | | — | | | — | | | — | Corporate | | | 482 | | | 2,758 | | | 3,240 | Total | | $ | 760 | | $ | 3,471 | | $ | 4,231 |
|
| Schedule of restructuring reserve |
Other amounts reported as restructuring and restructuring-related costs in the accompanying Consolidated Statements of Earnings and Comprehensive Income have been summarized in the notes to the table (in thousands): | | | | | | | | | | | | Year ended June 30, 2026 | | | Employee | | Asset-related | | | | | severance | | and other | | Total | Expense incurred in the fourth quarter of 2026 | | $ | 760 | | $ | 3,471 | | $ | 4,231 | Cash payments | | | (314) | | | (2,395) | | | (2,709) | Non-cash adjustments | | | — | | | — | | | — | Accrued restructuring as of June 30, 2026 | | $ | 446 | | $ | 1,076 | | $ | 1,522 |
|
| Restructuring Plan to Optimize Global Manufacturing |
|
| Restructuring |
|
| Schedule of restructuring charges |
The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands): | | | | | | | | | Year Ended | | Year Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | Cost of sales | | $ | 2,084 | | $ | 11,471 | Selling, general and administrative(1) | | | 6,825 | | | 84,160 | Total | | $ | 8,909 | | $ | 95,631 |
| (1) | Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. |
Restructuring and restructuring-related costs by segment are as follows (in thousands): | | | | | | | | | | | | | | | | Year ended June 30, 2026 | | | | | Employee | | | Asset-related | | | Recovery of | | | | | | | | severance | | | and other | | | assets held-for-sale | | | Total | | Protein Sciences | | $ | 2,374 | | $ | 6,901 | | $ | — | | $ | 9,275 | | Diagnostics and Spatial Biology | | | 2,993 | | | 197 | | | (6,789) | | | (3,599) | | Corporate | | | 1,314 | | | 1,919 | | | — | | | 3,233 | | Total | | $ | 6,681 | | $ | 9,017 | | $ | (6,789) | | $ | 8,909 | |
| | | | | | | | | | | | | | | Year ended June 30, 2025 | | | | Employee | | | Asset-related | | | Recovery of | | | | | | | severance | | | and other | | | assets held-for-sale | | | Total | Protein Sciences | | $ | — | | $ | 11,471 | | $ | — | | $ | 11,471 | Diagnostics and Spatial Biology | | | — | | | — | | | 83,059 | | | 83,059 | Corporate | | | 1,041 | | | 60 | | | — | | | 1,101 | Total | | $ | 1,041 | | $ | 11,531 | | $ | 83,059 | | $ | 95,631 |
|
| Schedule of restructuring reserve |
Other amounts reported as restructuring and restructuring-related costs in the accompanying Consolidated Statements of Earnings and Comprehensive Income have been summarized in the notes to the table (in thousands): | | | | | | | | | | | | | | | | | | | | | | Impairment (Recovery) | | | | | | Employee | | Asset-related | | | of assets | | | | | severance(1) | | and other(2) | | | held-for-sale | | Total | Expense incurred in the fourth quarter of 2025 | | $ | 1,041 | | $ | 11,531 | | $ | 83,059 | | $ | 95,631 | Cash payments | | | — | | | — | | | — | | | — | Non-cash adjustments | | | — | | | (11,471) | | | (83,059) | | | (94,530) | Accrued restructuring as of June 30, 2025 | | $ | 1,041 | | $ | 60 | | $ | — | | $ | 1,101 | Expense incurred in fiscal 2026 | | $ | 6,681 | | $ | 9,017 | | $ | (6,789) | | $ | 8,909 | Cash payments | | | (6,534) | | | (9,077) | | | — | | | (15,611) | Non-cash adjustments | | | — | | | — | | | 6,789 | | | 6,789 | Accrued restructuring as of June 30, 2026 | | $ | 1,188 | | $ | — | | $ | — | | $ | 1,188 |
| (1) | Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages. |
| (2) | Primarily relates to impairment of inventory and equipment. |
|
| Restructuring Plan to Recover Operating Margins |
|
| Restructuring |
|
| Schedule of restructuring charges |
The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands): | | | | | | | | | Year Ended | | | June 30, | | | 2026 | | 2025 | Cost of sales | | $ | 1,155 | | $ | 8,585 | Selling, general and administrative(1) | | | — | | | 5,832 | Total | | $ | 1,155 | | $ | 14,417 |
| (1) | Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. |
Restructuring and restructuring-related costs by segment are as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | Year ended June 30, | | | 2026 | | 2025 | | | | Employee | | | Asset-related | | | | | | Employee | | | Asset-related | | | | | | | severance | | | and other | | | Total | | | severance | | | and other | | | Total | Protein Sciences | | $ | 769 | | $ | 386 | | $ | 1,155 | | $ | 2,425 | | $ | 10,972 | | $ | 13,397 | Diagnostics and Spatial Biology | | | — | | | — | | | — | | | 411 | | | — | | | 411 | Corporate | | | — | | | — | | | — | | | 609 | | | — | | | 609 | Total | | $ | 769 | | $ | 386 | | $ | 1,155 | | $ | 3,445 | | $ | 10,972 | | $ | 14,417 |
|
| Schedule of restructuring reserve |
Other amounts reported as restructuring and restructuring-related costs in the accompanying Consolidated Statements of and Comprehensive Earnings have been summarized in the notes to the table (in thousands): | | | | | | | | | | | | Employee | | Asset-related | | | | | severance(1) | | and other(2) | | Total | Expense incurred in the first quarter of 2025 | | $ | 2,852 | | $ | 7,417 | | $ | 10,269 | Incremental expense incurred in remainder of 2025 | | | 593 | | | 3,555 | | | 4,148 | Cash payments | | | (2,223) | | | (1,131) | | | (3,354) | Non-cash adjustments | | $ | — | | $ | (9,841) | | $ | (9,841) | Accrued restructuring as of June 30, 2025 | | $ | 1,222 | | $ | — | | $ | 1,222 | Incremental expense incurred in fiscal 2026 | | | 769 | | | 386 | | | 1,155 | Cash payments | | | (1,743) | | | (386) | | | (2,129) | Accrued restructuring as of June 30, 2026 | | $ | 248 | | $ | — | | $ | 248 |
| (1) | Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. |
| (2) | Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites. |
|
| Fiscal Year 2024 Restructuring Actions |
|
| Restructuring |
|
| Schedule of restructuring charges |
The restructuring and restructuring-related charges, including the impairment (recovery) of assets held-for-sale, for periods presented were recorded in the Consolidated Statements of Earnings and Comprehensive Income as follows (in thousands): | | | | | | | | | Year Ended | | | June 30, | | | | 2025 | | | 2024 | Cost of sales | | $ | — | | $ | 3,349 | Selling, general and administrative(1) | | | (1,191) | | | 30,638 | Total | | $ | (1,191) | | $ | 33,987 |
| (1) | Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. |
Restructuring and restructuring-related costs by segment are as follows (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | Year ended June 30, | | | 2025 | | 2024 | | | | Employee | | | Asset-related | | | Recovery of | | | | | | Employee | | | Asset-related | | | Impairment of | | | | | | | severance | | | and other | | | assets held-for-sale | | | Total | | | severance | | | and other | | | assets held-for-sale | | | Total | Protein Sciences | | $ | 127 | | $ | 73 | | $ | (2,557) | | $ | (2,357) | | $ | 3,483 | | $ | 5,130 | | $ | 21,963 | | $ | 30,576 | Diagnostics and Spatial Biology | | | — | | | — | | | — | | | — | | | 1,007 | | | 224 | | | — | | | 1,231 | Corporate | | | 86 | | | 1,080 | | | — | | | 1,166 | | | 1,153 | | | 1,027 | | | — | | | 2,180 | Total | | $ | 213 | | $ | 1,153 | | $ | (2,557) | | $ | (1,191) | | $ | 5,643 | | $ | 6,381 | | $ | 21,963 | | $ | 33,987 |
|
| Schedule of restructuring reserve |
Other amounts reported as restructuring and restructuring-related costs in the accompanying Consolidated Statements of Earnings and Comprehensive Income have been summarized in the notes to the table (in thousands): | | | | | | | | | | | | | | | | | | | | | | Recovery | | | | | | | Employee | | | Asset-related | | | of assets | | | | | | | severance(1) | | | and other(2) | | | held-for-sale | | | Total | Expense incurred in the second quarter of 2024 | | | 4,882 | | | 504 | | | 6,038 | | | 11,424 | Incremental expense incurred in the remainder of 2024 | | | 542 | | | 5,877 | | | 15,926 | | | 22,345 | Cash payments | | | (4,882) | | | (2,800) | | | — | | | (7,682) | Non-cash adjustments | | | — | | | (3,391) | | | (21,963) | | | (25,354) | Adjustments(3) | | | 219 | | | — | | | — | | | 219 | Accrued restructuring actions balance as of June 30, 2024 | | $ | 761 | | $ | 190 | | $ | — | | $ | 952 | Incremental expense incurred in fiscal 2025 | | | 213 | | | 1,153 | | | (2,557) | | | (1,191) | Cash payments | | | (974) | | | (1,343) | | | — | | | (2,317) | Non-cash adjustments | | | — | | | — | | | 2,557 | | | 2,557 | Accrued restructuring actions balance as of June 30, 2025 | | $ | — | | $ | — | | $ | — | | $ | — |
| (1) | Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. |
| (2) | Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. |
| (3) | Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. |
|